All In Biotech

Drug Trial Radar · NCT06609226

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

An Open-label, Multi-centre, Rollover Study to Characterise Long-term Safety and Efficacy of Etavopivat in Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia and Have Completed a Treatment Period in an Etavopivat Study

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Jan 10, 2025

Primary completion

Dec 30, 2030

Study completion Dec 30, 2030

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Sep 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.

Conditions

  • Sickle Cell Disease
  • Thalassemia

Interventions

  • Etavopivat ADrug

    Participants will receive an oral dose of Etavopivat A.

  • Etavopivat BDrug

    Participants will receive an oral dose of Etavopivat B.

  • Etavopivat CDrug

    Participants will receive an oral dose of Etavopivat C.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treatment emergent adverse events (TEAEs), reported for each indication and age group separatelyTime frame: Baseline (week 0 of FLORAL) up to end of study (up to week 316)
  2. Number of adverse reactions, reported for each indication and age group separatelyTime frame: Baseline (week 0 of FLORAL) up to end of study (up to week 316)

Locations

107 sites in 17 countries. Site status is shown where the registry gives one.

  • Univ of Alabama Birmingham

    Birmingham, Alabama · Active not recruiting

  • Phoenix Children's Hsptl

    Phoenix, Arizona · Active not recruiting

  • Children's Hospital Los Angeles - Endocrinology

    Los Angeles, California · Active not recruiting

  • Children's Hospital Los Angeles - Endocrinology

    Los Angeles, California · Recruiting

  • UCSF Oakland Benioff ChildHosp

    Oakland, California · Active not recruiting

  • UCSF Oakland Benioff ChildHosp

    Oakland, California · Recruiting

  • Children's Hosp Of Orange

    Orange, California · Completed

  • University Of California Irvine

    Orange, California · Active not recruiting

  • University of Connecticut

    Farmington, Connecticut · Active not recruiting

  • Children's National Medical Center

    Washington D.C., District of Columbia · Completed

  • Foundation for Sickle Cell Disease Research

    Hollywood, Florida · Active not recruiting

  • Univ of Miami/SCCC

    Miami, Florida · Completed

  • Emory University School of Medicine

    Atlanta, Georgia · Active not recruiting

  • Children's Healthcare Atlanta

    Atlanta, Georgia · Recruiting

  • Center for Blood Disorders Augusta University

    Augusta, Georgia · Active not recruiting

  • Univer Of Illinois at Chicago

    Chicago, Illinois · Recruiting

  • Children's Hosp-New Orleans

    New Orleans, Louisiana · Completed

  • Boston Medical Center

    Boston, Massachusetts · Active not recruiting

  • Washington University-St.Louis

    St Louis, Missouri · Active not recruiting

  • NYC Health+Hospitals

    Brooklyn, New York · Active not recruiting

  • Columbia University Medical Center_New York_0

    New York, New York · Recruiting

  • Columbia University Medical Center_New York_0

    New York, New York · Not yet recruiting

  • Weill Cornell Med Coll-NYPH

    New York, New York · Active not recruiting

  • Jacobi Medical Center

    The Bronx, New York · Active not recruiting

  • Montefiore Medical Center

    The Bronx, New York · Active not recruiting

  • Atrium Levine Children's/Atrium Health

    Charlotte, North Carolina · Not yet recruiting

  • Duke University_Durham

    Durham, North Carolina · Recruiting

  • East Carolina Univ-Greenville

    Greenville, North Carolina · Active not recruiting

  • East Carolina University_Greenville

    Greenville, North Carolina · Completed

  • Atrium Health-Wake Forest Bapt

    Winston-Salem, North Carolina · Active not recruiting

  • Cincinnati Child's Hsp Med Ctr

    Cincinnati, Ohio · Active not recruiting

  • Neuro-Behavioral Clinical Research

    North Canton, Ohio · Active not recruiting

  • Medical University Of South Carolina_Charleston

    Charleston, South Carolina · Active not recruiting

  • Methodist University Hospital

    Memphis, Tennessee · Active not recruiting

  • Texas Children's Hospital_Houston

    Houston, Texas · Recruiting

  • UT Health University of Texas

    Houston, Texas · Recruiting

  • Virginia Comm Univ Medical Ctr

    Richmond, Virginia · Completed

  • Mary Bridge Children's Health

    Tacoma, Washington · Active not recruiting

  • Versiti, CCBD_Milwaukee

    Milwaukee, Wisconsin · Recruiting

  • St Pauls Hospital

    Vancouver, British Columbia, Canada · Active not recruiting

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.